- AU$230.15m
- AU$303.42m
- AU$214.03m
- 83
- 42
- 84
- 77
Annual income statement for Probiotec, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
R2019 June 30th | 2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 73.2 | 107 | 121 | 182 | 214 |
| Cost of Revenue | |||||
| Gross Profit | 22.7 | 31.8 | 34.6 | 57.2 | 64.3 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 68.7 | 98.3 | 113 | 164 | 198 |
| Operating Profit | 4.52 | 8.9 | 7.72 | 18 | 15.6 |
| Net Income Before Taxes | 4.52 | 8.9 | 7.72 | 18 | 15.6 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 3.74 | 6.44 | 5.07 | 13.7 | 11 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | 11.3 | 3.51 | 4.85 | 13.7 | 11 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 11.3 | 3.51 | 4.85 | 13.7 | 11 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.058 | 0.096 | 0.037 | 0.181 | 0.137 |
| Dividends per Share | |||||
| Special Dividends per Share |